Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Ultragenyx Pharmaceutical Inc.

Advances in™ Rare Diseases: Fatty Acid Oxidation Disorders – Improving Energy Production Through Alternative Sources

Release Date: December 31, 2018
Expiration Date: December 31, 2019
Media: Internet - based

Activity Overview

This activity, Advances in™ Rare Diseases: Fatty Acid Oxidation Disorders – Improving Energy Production Through Alternative Sources, developed in Physicians’ Education Resource®, LLC, (PER®) established Advances in™ legacy format, will increase awareness of the presenting signs and symptoms of long-chain fatty acid oxidation disorders (LC-FAODs). Management strategies to improve quality of life (QoL) and emerging new therapies for LC-FAODs will be highlighted, with an emphasis on individualized treatment. Case vignettes throughout will bring important information on this uncommon but highly burdensome metabolic disorder into clinical practice.

You will hear experts discuss ongoing clinical trials and early experience with compassionate use of the novel agent triheptanoin, as they provide their perspectives on how new treatments may impact long-term outcomes of patients with LC-FAOD, and guide participants on potential application to clinical practice.

Benefits of Completing Activity

By participating in this exciting program, you will learn about:

  • The pathophysiology and symptoms of LC-FAODs phenotypes, especially in pediatric patients
  • Individualized management strategies to improve QoL and outcomes for patients with LC-FAOD
  • The latest clinical data to tailor therapeutic strategies for patients with LC-FAOD

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Ultragenyx Pharmaceutical Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward pediatricians, PCPs, NPs, PAs, and other healthcare professionals involved in the care of patients with LC-FAOD.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Define the pathophysiology and symptoms of LC-FAOD
  • Identify disease management options to achieve individualized care for patients with LC-FAOD
  • Apply knowledge of the mechanisms of action and adverse drug reactions of emerging therapies to clinical management of patients with LC-FAOD

Faculty, Staff, and Planners' Disclosures


Jerry Vockley, MD, PhD
University of Pittsburgh
Cleveland Family Endowed Chair in Pediatric Research
Professor of Human Genetics

Children's Hospital of Pittsburgh
Chief of Medical Genetics
Director, Center for Rare Disease Therapy
Pittsburgh, Pennsylvania

Disclosures: Grant/Research Support: NIH, Reno Pharmaceuticals, Ultragenyx Pharmaceuticals Inc. Investigational/Off-Label Use of Drugs/Devices Disclosure: Triheptanoin (in clinical trials)

Nicola Longo, MD, PhD
Professor and Chief
Division of Medical Genetics
Department of Pediatrics
University of Utah
Salt Lake City, Utah

Disclosures: Grant/Research Support: Ultragenyx Pharmaceuticals Inc. ( support for participation in clinical trials) Investigational/Off-Label Use of Drugs/Devices Disclosure: Triheptanoin (in clinical trials)

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Related CME Activites

Become a Member

Forgot Password?
Calendar of Events
Filter By